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Carcinomas are comprised of transformed epithelial cells that are
supported in their growth by a dedicated neovasculature. How the
genetic milieu of the epithelial compartment influences tumor
angiogenesis is largely unexplored. Drugs targeted to mutant
cancer genes may act not only on tumor cells but also, directly or
indirectly, on the surrounding stroma. We investigated the role of
the BRAFV600E oncogene in tumor/vessel crosstalk and analyzed
the effect of the BRAF inhibitor PLX4720 on tumor angiogenesis.
Knock-in of the BRAFV600E allele into the genome of human epithe-
lial cells triggered their angiogenic response. In cancer cells harbor-
ing oncogenic BRAF, the inhibitor PLX4720 switches off the ERK
pathway and inhibits the expression of proangiogenic molecules.
In tumor xenografts harboring the BRAFV600E, PLX4720 extensively
modifies the vascular network causing abrogation of hypoxia.
Overall, our results provide a functional link between oncogenic
BRAF and angiogenesis. Furthermore, they indicate how the tumor
vasculature can be “indirectly” besieged through targeting of a
genetic lesion to which the cancer cells are addicted.
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Angiogenesis is a pivotal process for the growth, maintenance,and spread of the majority of solid tumors. In the early steps
of carcinogenesis, tumor cells require oxygen and nutrients,
which are supplied by newly formed vessels. During later phases
of cancer progression, blood vessels provide one of the most
important routes for tumor escape and metastasization (1, 2).
Notably, the structure of the vascular network dramatically alters
tumor features. Tumor vessels are disorganized, with perfusion
defects resulting in metabolic changes, hypoxia, and increase in
interstitial pressure (3). At the clinical level, these features are
associated with a more aggressive phenotype and a reduction of
drug delivery to the tumor mass (4, 5).
The angiogenic process is triggered and controlled by the
cancer cells, which carry genetic lesions that are causally associ-
ated with the neoplastic process. Understanding how individual
genetic lesions in oncogenes and tumor suppressor genes affect
directly or indirectly the angiogenic process is a fundamental
question that has been largely unexplored. It has been suggested
that alterations in oncogenes involved in the intracellular MAPK
signaling cascade play a central role in regulating tumor angio-
genesis (6). For example, KRAS activating mutations are thought
to sustain the chaotic tumor vasculature by up-regulating the
transcription of angiogenic inducers, including VEGF-A and IL-8
(7–9). BRAF binds to and is the main downstream effector of
KRAS. Whether and to what extent genetic alterations affect
BRAF-regulated angiogenesis is presently unclear. The most
common BRAF mutation is a valine-to-glutamate transition
(V600E), which results in constitutive activation of the kinase
activity. BRAFV600E is causally involved in the onset and pro-
gression of several cancers, including melanoma, papillary thy-
roid, colorectal, and ovarian tumors (10–12), and is often asso-
ciated with a particularly poor prognosis (13–17).
In addition to activation of aberrant cell proliferation,
BRAFV600E modulates tumor–stroma interaction and supports
cancer invasiveness by influencing the expression of metallo-
proteinases and cytokines (IL-6 and IL-10) involved in tumor-
immune escape (18, 19). Furthermore, BRAFV600E affects tumor
environment by enhancing the expression of HIF1α (20–22),
VEGF-A and IL-8 (23–25) and inhibiting the angiogenic blocker
thrombospondin 1 (26).
Specific and selective BRAF kinase inhibitors, such as
PLX4032/PLX4720, have recently shown remarkable clinical
success in patients with melanoma carrying the BRAFV600E mu-
tation (27–29).
Considering the putative role of mutant BRAF in modulating
cancer cell function and microenvironment, we hypothesized
that the efficacy of PLX4720 could result from targeting the
epithelial and the stromal tumor compartments. In this work,
we assessed the contribution of BRAFV600E oncogene in pro-
moting angiogenesis, and investigated whether the BRAF in-
hibitor PLX4720 affects tumor angiogenesis and hypoxia.
Results
BRAFV600E Drives Angiogenesis in Chicken Chorioallantoic Membrane.
To study the specific influence of BRAFV600E on angiogenesis,
we used an isogenic model in which BRAFV600E was knocked-in
through homologous recombination into the genome of the
nontumorigenic human mammary epithelial cell line (hTERT-
HME1) (30). As a result, the mutant allele is expressed under its
endogenous promoter at levels comparable to wild type (WT)
thus overcoming the experimental drawbacks associated with
plasmid-driven ectopic overexpression.
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We used the chicken chorioallantoic membrane (CAM) assay
to assess whether BRAFV600E could modulate angiogenesis.
Compared with WT, BRAFV600E cells growing on CAM led to
a disorganized vasculature with several hemorrhagic areas as
measured by an arbitrary “angiogenic index” (Fig. 1 A, a and b,
and B). The quantification of chicken endothelium within the
epithelial plugs revealed that BRAFV600E increased the re-
cruitment of endothelial cells (ECs) (Fig. 1 A, c–f, and C).
We next compared the transcriptional profile of genes in-
volved in angiogenesis and inflammation between BRAFV600E
and parental hTERT-HME1 cells. To avoid clonal variability,
two independent BRAFV600E KI clones were evaluated. The
transcription analysis was performed in standard culture con-
ditions (on plastic) and on CAM. This comprehensive approach
revealed that oncogenic BRAFV600E enhanced the expression of
several proangiogenic and proinflammatory molecules, including
VEGF-A and C, TGF-α, and chemokines, such as CXCL1-2–3,
IL1β, and IL8 (Fig. S1 shows a list of differentially expressed
genes). Importantly, results from cells plated on CAM mirrored
those obtained in vitro, indicating that the chicken embryo mi-
croenvironment does not influence the transcriptional landscape
of the xenografted cells.
The finding that oncogenic BRAFV600E triggers up-regulation
of factors known to modulate angiogenesis led us to hypothesize
that the occurrence of this mutation in epithelial cells might
affect the endothelium. Among the factors that were pinpointed
by the transcriptional profile, we focused on VEGF-A because
this molecule is a well known master switch of the angiogenic
program. BRAFV600E KI cells released higher amounts of
VEGF-A in the supernatant that enhanced EC migration com-
pared with the WT counterpart (Fig. 1 D and E). The chemo-
tactic effect of oncogenic BRAF on the ECs was abrogated by an
anti-VEGF blocking antibody, but not by an unrelated Ig (Fig.
1E). This observation supports the pivotal role of VEGF-A in
BRAFV600E -driven angiogenesis.
PLX4720 Exerts Cytostatic and Antiangiogenic Activities in Tumor
Harboring BRAFV600E.We next assessed whether the results obtained
by using the non-transformed isogenic cells might hold true in
cancer cells carrying the BRAFV600E allele. Cell lines of colorectal
cancer (COLO205) and melanoma (SK-MEL-28) origin were se-
lected because these tumor types frequently harbor mutations in
the BRAF gene (10). As expected, in vitro treatment with the
specific BRAFV600E inhibitor PLX4720 resulted in cell growth
inhibition and ERK inactivation in both cell lines, whereas AKT
phosphorylation was not affected (Fig. 2 A and B). Colorectal
cancer cells carrying WT BRAF (DiFi) were used as control and
proved insensitive to PLX4720 treatment (Fig. 2 A and B).
We next measured the effect of PLX4720 in vivo by growing
COLO205 and SK-MEL-28 subcutaneously in immunocompro-
mised mice. PLX4720 induced a prolonged cytostatic effect in
both xenograft models (Fig. 2 C and D, a and b). Importantly,
PLX4720-treated tumors did not show evident shrinkage and,
despite an initial regression in SK-MEL-28, at the end of the
experiments, tumor size was stabilized but not reduced. This was
further supported by the analysis of proliferation and apoptosis
assessed through Ki-67 staining and activation of caspase 3, re-
spectively. We found that PLX4720 markedly inhibited tumor
cell proliferation, whereas it was ineffective in inducing apoptosis
(Fig. 2 D, c–f, E, and F).
We then investigated the impact of PLX4720 on tumor an-
giogenesis in vivo. As differences in the tumor vasculature might
be influenced by cell proliferation and/or tumor size, we in-
troduced a third control group that involved samples obtained
when treatment was started. These samples (hereafter referred
to as “start point”) were carefully chosen to have approximately
the same volume of PLX4720-treated tumors. The comparative
analysis of the three groups allowed us to investigate the effect of
PLX4720 on tumor vasculature. As shown in Fig. 3A, PLX4720
induced profound changes in vascular architecture in COLO205
and SK-MEL-28 tumors. In the absence of treatment, the vas-
cularized area in COLO205 tumors did not change throughout
the experiment. Conversely, the area occupied by vessels in-
creased in PLX4720-treated samples compared with the vehicle
and start-point samples (Fig. 3B). This phenotype is likely the
consequence of morphological changes in vascular structure.
Fig. 1. KI of the BRAFV600E allele in hTERT-HME1 cells enhances angio-
genesis in CAM assay and increases VEGF-mediated migration of ECs. (A)
Representative images of hTERT-HME1 cells plated on the CAM (a and b).
(Scale bar: 1 mm.) Immunofluorescence analysis of hTERT-HME1 cells plated
on the CAM. Human epithelial cells were stained with the HLA marker
(green) whereas blood vessels were labeled with the vWF, which is specific
for ECs (red) (c–f). Arrows indicate blood vessels. (Scale bar: 100 μm.) (B)
Qualitative assessment of angiogenesis (angiogenic index) in the CAM assay
(Materials and Methods). Bars represent the number of CAM samples that
exhibit low, medium, or high angiogenesis in parental or BRAFV600E mutant
cells. Measurements were performed by two observers in blinded fashion.
(C) Quantitative analysis of vWF intensity fluorescence mean in hTERT-HME1
plugs. Data are expressed as fold change mean ± SEM (§P < 0.05, Student t
test; WT hTERT-HME1, n = 6; BRAFV600E KI hTERT-HME1, n = 9 samples). (D)
Quantification of secreted VEGF-A in hTERT-HME1 cells by ELISA. Data are
expressed as mean ± SD of a technical replicate and are representative of
three independent experiments. (E) Migration of human ECs is enhanced by the
supernatant of hTERT-HME1 BRAFV600E KI cells compared with the WT coun-
terpart. Two different clones of BRAFV600E KI were analyzed (KI-A and KI-B).
SF, serum freemedium. VEGF blocking antibody (VEGF-Ab), but not unrelated
Ig, abolished BRAFV600E -induced cell migration. Bars represent the mean ±
SEM of the number of migrated cells of three samples (§P < 0.05, Student
t test). The representative of three independent experiments is shown.
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Indeed, blood vessels were enlarged and chaotic in control
tumors and thinner with an organized architecture in PLX4720-
treated samples (Fig. 3A, a–c). The average blood vessel di-
ameter decreased from 33 μm or 31 μm in start point and vehicle
groups, respectively, to 19 μm in treated samples (Fig. 3C).
Surprisingly, despite these evident morphological differences, the
blood vessel coverage by pericytes was unaffected by PLX4720
treatment (Fig. S2).
In SK-MEL-28 xenografts, the vascularized area increased in
vehicle-treated tumors whereas PLX4720 reduced the area oc-
cupied by vessels (Fig. 3B). Similar to what was observed in
COLO205, PLX4720 treatment of SK-MEL-28 tumors increased
the vascular surface area compared with start-point tumor. Fur-
thermore, the morphology of the vascular network in SK-MEL-28
was markedly modified and the blood vessel average diameter
was reduced from 14 μm compared with 23 μm and 22 μm in
start-point and vehicle groups, respectively (Fig. 3 A, d–f, and C).
PLX4720 Abrogates Hypoxia in BRAFV600E Tumors. The aberrant
morphology of blood vessels was strongly suggestive of altered
functionality of the microvasculature. We confirmed this hy-
pothesis by the analysis of tumor perfusion before and after
PLX4720 treatment of COLO205 tumors. Tissue perfusion by
blood vessels was strongly increased in PLX4720-treated tumors
compared with vehicle or start-point groups, indicating an im-
proved functionality of microvasculature (Fig. 3D). Blood per-
fusion correlates with improved tissue oxygenation, which causes
deep changes in the overall features of tumor parenchyma (3).
We therefore studied the effect of PLX4720 on intratumoral
hypoxia in COLO205 and SK-MEL-28 xenografts and found that
PLX4720 prominently abolished hypoxia in treated tumors
compared with vehicle or start-point tumors (Fig. 4 A, a–c and g–
i, and B). Moreover, analysis of tumor tissues revealed that the
modification of vascular structure by PLX4720 was linked to
reduced necrotic area in COLO205 and SK-MEL-28 xenografts
(Fig. 4 A d–f and j–l, and C). These results indicate that the effect
on hypoxia is independent from tumor growth and has implica-
tions for the therapeutic activity of PLX4720.
Importantly, targeting of angiogenesis by BRAF inhibition
showed significant differences with respect to classical “VEGF
directed” antiangiogenic therapy. Treatment of COLO205 tumors
with the VEGF-blocking antibody bevacizumab resulted in sta-
bilization of tumor growth and strongly reduced microvascular
density (Fig. 5 A, B, g and h, and C). Concomitantly, tissue per-
fusion was impaired, and this led to persistent hypoxia and ne-
crosis (Fig. 5 B and D–F). The comparison between the two
Fig. 2. PLX4720 inhibits proliferation and turns off MAPK signaling in tumor cells carrying BRAFV600E. (A) Proliferation of COLO205 and SK-MEL-28, harboring
BRAFV600E, and BRAF WT DiFi cells, was assessed with increased PLX4720 concentration. Data are expressed as percentage of viability compared with vehicle
by the ATP assay. Mean ± SD of two independent experiments performed in quadruplicate is shown. (B) Biochemical analysis of phospho-ERK and phospho-
AKT (Ser473 and Thr308) in COLO205, SK-MEL-28, and DiFi cells. Protein loading was normalized by vinculin. Starved cells were stimulated for 30 min with
2.5% FBS plus 1 μM PLX4720 or vehicle. (C) Tumor growth curve of COLO205 and SK-MEL-28 xenografts. COLO205 and SK-MEL-28 xenografts were treated
with PLX4720 60 mg/kg or vehicle for 2 wk after tumor volume reached an average of 150 to 200 mm3. Arrows indicate the time point at which treatment was
started. Data are presented as mean tumor volume ± SEM. (D) Representative images of COLO205 tumors (a and b). (Scale bar: 4 mm.) Representative images
of Ki-67 staining in COLO205 (c and d) and SK-MEL-28 (e and f) xenografts. (Scale bar: 100 μm.) (E) Quantification of proliferating cells by Ki-67 staining in
COLO205 and SK-MEL-28 xenografts. Bars show the mean of positive cells per 10× field ± SD (§P < 0.0001, Student t test). For COLO205, vehicle, n = 4 mice;
PLX4720, n = 6 mice; for SK-MEL-28, vehicle, n = 4 mice; PLX4720, n = 5 mice. (F) Biochemical analysis of cleaved caspase 3 in protein extract of COLO205 and
SK-MEL-28 xenografts. Protein loading was normalized by vinculin. At least four independent samples were evaluated.

















approaches suggests that antiangiogenic therapy based on in-
hibition of oncogenes in the epithelial compartment has a
greater chance to positively affect the vascular network com-
pared with blockade of the VEGF pathway.
PLX4720 Down-Regulates Expression and Secretion of Proangiogenic
Factors in BRAF Mutant Cancer Cells. To further assess whether the
antiangiogenic effect of PLX4720 was direct (on the tumor
vasculature) or indirect (via epithelial cells), we investigated if
PLX4720 affected ECs in vitro. We found that proliferation and
migration of ECs were unaffected by drug treatment (Fig. S3),
thus ruling out a possible direct effect of BRAF inhibition on the
endothelial compartment. We next considered if PLX4720 was
capable of modulating the production of angiogenic molecules
by cancer cells, which in turn might influence the tumor envi-
ronment. To assess this, we analyzed the effect of BRAF in-
hibition on the expression of angiogenic factors in colorectal and
melanoma cells carrying mutant BRAF. We found that, upon
PLX4720 treatment, multiple mediators of angiogenesis (e.g.,
CXCL1-2–3, IL-1β, and IL-8 and VEGF-A) were down-regu-
lated in COLO205 and SK-MEL-28. On the contrary, the same
genes were not modulated in the BRAF WT DiFi colorectal
cancer cells (Fig. 6 A and B). Additionally, the effect of PLX4720
on VEGF production was not modified by hypoxia, an experi-
mental condition that mimics tumors environment (Fig. 6B).
Oncogenic BRAF is a key player in the activation of the MAPK-
ERK signaling cascade. We therefore reasoned that the control
of VEGF expression by PLX4720 might be caused by the in-
hibition of MAPK signaling. Treatment with the MEK inhibitor
AZD6244 decreased VEGF secretion, thus suggesting that
MAPK signaling pathway is essential for VEGF expression (Fig.
6B). ERK has been previously shown to influence protein
translation through the control of the phosphorylation status of
Fig. 3. PLX4720 treatment stabilizes blood vessels in COLO205 and SK-MEL-
28 xenograft models. (A) Representative images of immunofluorescence
analysis with the CD31 endothelial marker (green) in COLO205 (a–c) and SK-
MEL-28 (d–f) tumors. (Scale bar: 100 μm.) (B) Percentage of surface area
occupied by vessels quantified by CD31 staining. Bars show mean ± SEM.
(§§P < 0.001 and §P < 0.01, Student t test). For COLO205, start point, n = 8
mice; vehicle, n = 9 mice; PLX4720, n = 14 mice; for SK-MEL-28, start point,
n = 6 mice; vehicle, n = 5 mice; PLX4720, n = 5 mice. (C) Quantification of
blood vessel lumen diameter. Red bars represent the median for each group
(§§P < 0.0001, Student t test). Dots indicate the individual vessels measured
for the indicated cell lines. (D) Representative images of colocalization
analysis between perfused beads (red) and CD31 (green) in COLO205. (Scale
bar: 50 μm.) Quantification is shown as mean ± SEM of colocalization area
(in μm2; §§P < 0.01 and §P < 0.05, Student t test). COLO205, start point, n = 39
blood vessels; vehicle, n = 30 blood vessels; PLX4720, n = 35 blood vessels.
S.p., start point; V, vehicle; P, PLX4720.
Fig. 4. PLX4720 treatment abolishes tumor hypoxia and decreases necrosis
in COLO205 and SK-MEL-28 xenograft models. Histological analysis of
COLO205 and SK-MEL-28 xenografts before and after PLX4720 treatment.
(A) Representative images of pimonidazole and H&E staining in COLO205
(a–c and d–f) and SK-MEL-28 (g–i and j–l) tumors. (Scale bar: 100 μm.) (B)
Quantification of the hypoxic area (percentage) by pimonidazole staining.
Bars show mean ± SEM (§§P < 0.005 and §P < 0.05, Student t test). For
COLO205, start point, n = 7 mice; vehicle, n = 8 mice; PLX4720, n = 8 mice; for
SK-MEL-28, start point, n = 6 mice; vehicle, n = 5 mice; PLX4720, n = 5 mice.
(C) Quantification of necrotic area after H&E staining in COLO205 and SK-
MEL-28 xenografts. Bars represent the percentage mean area ± SEM (§§P <
0.01 and §P < 0.05, Student t test). For COLO205, start point, n = 8 mice;
vehicle, n = 9 mice; PLX4720, n = 14 mice; for SK-MEL-28, start point, n = 6
mice; vehicle, n = 5 mice; PLX4720, n = 5 mice.
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p90RSK1, 4EBP1, and eIF4E translation initiating factor. It is
known that activation of ERK induces the phosphorylation of
eIF4E by the MNK kinase (31) and of 4EBP1 by inactivation of
TSC2 through p90RSK (32). In turn, phosphorylation of 4EBP1
releases eIF4E, thus allowing protein translation. We found that
PLX4720 turns off the MAPK pathway in BRAFV600E mutated
cells, resulting in decreased phosphorylation of p90RSK1,
4EBP1, and eIF4E. The same effect could not be recapitulated
in DiFi cancer cells, demonstrating that it is dependent on the
presence of oncogenic BRAF (Fig. 6C). Overall, these results
indicate that BRAFV600E targeted by PLX4720 modifies the
proangiogenic program by acting on the MAPK pathway.
Discussion
To support the exponential growth of solid tumors, new blood
vessels are continuously formed (1, 2). This active process is
mainly sustained by cancer cells that produce and release an-
giogenic factors into the microenvironment, thus promoting
neoangiogenesis. Antiangiogenic therapies have been developed
to target this course of action, which is primarily driven by sol-
uble growth factors such as VEGF (33, 34).
Therapies aimed at interfering with the tumor microenviron-
ment and those that directly target cancer cells are often consid-
ered to represent two independent approaches. This discrepancy
occurs despite the fact that the epithelial and stromal compart-
ments are clearly linked at the structural and functional levels.
How activation of a given oncogene in epithelial cells modulates
the angiogenic response of the surrounding stromal cells is largely
unknown. We and others have shown that the mutational profile of
individual tumors affect their response to targeted therapies (35,
36). For example, EGFR kinase inhibitors are mainly active in lung
cancer cells carrying mutations in the receptor (37, 38); likewise,
the occurrence of KRAS mutations impairs the efficacy of anti-
EGFR monoclonal antibodies in colorectal cancer (39–41). These
findings are helping clinicians to match patients with appropriate
drugs, a process often referred to as personalized medicine. Clin-
ical evidence indicates that antiangiogenic therapies are also
mainly effective in distinct patient subpopulations, although the
molecular bases for this are still unknown (42–44). It is therefore
tempting to speculate that the genetic milieu of the epithelial
compartment dictates an individual’s response to antiangiogenic
therapies by modulating the tumor microenvironment.
In this work, we explored the possibility that the mutational
activation of an individual oncogene affects the angiogenic po-
tential of cancer cells. As a model, we chose BRAFV600E, one of
the most aggressive oncogenes frequently detected in colorectal
tumors and melanomas (10, 12). We took advantage of a KI
model, in which BRAF mutation has been introduced into the
genome of non-transformed epithelial cells, hence closely re-
capitulating the situation observed in human neoplasms (30). This
strategy overcomes the limitations of previous studies in which
expression of cancer alleles was driven by viral promoters, result-
ing in expression levels many fold greater than in an endogenous
setting. We report that BRAF mutant cells display up-regulation
of proangiogenic factors and actively recruited the endothelium. In
tumor cells, blockage of BRAFV600E with the specific PLX4720
inhibitor not only exerted a cytostatic activity, but influenced the
architecture of tumor vasculature. Notably, PLX4720 treatment
did not affect ECs directly; rather, it down-regulated the expres-
sion of angiogenic factors in tumor cells by switching off the
MAPK pathway and p90RSK-dependent translation.
Treatment with PLX4720 strongly influenced the morphology
of the tumor vasculature in the cellular models (COLO205 and
SK-MEL-28) that were analyzed. Specifically, the BRAF in-
hibitor modified the architecture and the functionality of the
vessels, which appeared more regularly shaped, and provided
a better perfusion of the tumor. Furthermore, in both COLO205
and SK-MEL-28, PLX4720 reduced necrosis and almost com-
pletely abrogated tumor hypoxia. We propose that, in addition to
the well established growth inhibitory activities on BRAF mutant
cancer cells, PLX4720 affects tumor growth by stabilizing the vas-
culature and ameliorating tissue perfusion. At least in the experi-
mental conditions we tested, BRAFV600E targeting by PLX4720
showed some advantageous features compared with the classical
anti-angiogenic therapy with bevacizumab. The latter clearly
reduced tumor growth and angiogenesis but did not improve
oxygenation or reduce hypoxia. These results are reminiscent of
data obtained in mouse models of pancreatic neuroendocrine
Fig. 5. Effect of bevacizumab on tumor growth and vasculature. COLO205
xenografts were treated with bevacizumab 10 mg/kg or vehicle for 2 wk
after tumor volume reached an average of 150 to 200 mm3. (A) Tumor
growth curve of COLO205; arrow indicates time point at which treatments
were started. Data are presented as mean tumor volume ± SEM of five
mice. (B) Representative images of H&E (a and b) and pimonidazole
staining (c and d) in COLO205. (Scale bar: 100 μm.) Colocalization analysis
between perfused beads (red) and CD31 (green) in COLO205 (e–h). (Scale
bar: 50 μm.) (C ) Percentage of surface area occupied by vessels quantified
by CD31 staining. Bars show mean ± SEM (§§P < 0.01, Student t test). Ve-
hicle, n = 5 mice; bevacizumab, n = 6 mice. (D) Analysis of colocalization
area between perfused beads and CD31. Quantification is shown as mean ±
SEM of colocalization area (in μm2; §§P < 0.01). Vehicle, n = 35 blood
vessels; bevacizumab, n = 15 blood vessels. (E ) Quantification of the per-
centage hypoxic area by pimonidazole staining. Bars show mean ± SEM.
Start point, n = 4 mice; vehicle, n = 5 mice; bevacizumab, n = 6 mice. (F )
Quantification of necrotic area by H&E staining. Bars represent the per-
centage mean area ± SEM. Start point, n = 4 mice; vehicle, n = 5 mice;
bevacizumab, n = 6 mice.

















tumor and glioblastoma, whereby compounds that inhibit VEGF
receptor 2 induce a marked hypoxia (45, 46).
Although the overall effect of BRAF inhibition was consistent
in the two cell types, treatment of SK-MEL-28 reduced the vas-
cularized area whereas the opposite occurred when COLO205
tumors were treated. A number of explanations could account for
this difference. It has been reported that the ratio of the VEGF-
A isoforms dictates the final shape of the vasculature and regu-
lates blood flow by influencing vessel size (47, 48). It is possible
that the VEGF isoforms and other cytokines are modulated to
different extents in the two models. Moreover, VEGF activities
may be finely tuned by specific coreceptors of VEGF-receptor 2
(e.g., neuropilins, integrins) that may be differentially expressed
on the capillaries of the two xenografts (49). Finally, the effect of
PLX4720 on SK-MEL-28 tumor vasculature is in line with the
phenotype observed by treating melanoma tumors with VEGF-
receptor inhibitor. As a matter of fact, in the SK-MEL-3 mela-
noma model, treatment with sunitinib caused a significantly de-
crease in vessel density, but the pressure of oxygen and uptake of
contrast agent used in resonance imaging were increased (50).
The efficacy and safety of antiangiogenic agents has recently been
questioned based on the discovery that reducing the blood supply to
cancer cells causes hypoxia and could favor metastasization (45, 46,
51). In this regard, our work suggests that the pharmacological in-
hibition of an oncogenic mutation, which causally contributes to the
imbalance between pro- and antiangiogenic mediators, may repre-
sent another valuable strategy to target tumor angiogenesis.
Materials and Methods
Isogenic Cell Model. hTERT-HME1 cells were purchased from American Type
Culture Collection, and KI cells for BRAFV600E were obtained through adenoas-
sociated viral-mediated homologous recombination as previously described (30).
CAM Assay. Fertilized chicken embryos were incubated for 3 d at 37 °C and
70% humidity. A small hole was made over the air sac at the end of the egg,
and a second hole was made directly over the embryonic CAM. After 10 d,
hTERT-HME1 WT or BRAFV600E KI cells were inoculated onto CAM for 48 h. In
detail, 1 × 106 cells were mixed with 50 μL of serum-free DMEM plus 50 μL of
Matrigel (growth factors reduced; Becton-Dickinson) and dropped onto
the CAM to form a plug. CAMs were fixed with PBS solution/3.7% para-
formaldehyde for 10 min at room temperature, and images were taken with
a QIcam FAST1394 digital color camera (QImaging) connected to the ste-
reomicroscope (model SZX9;Olympus). SI Materials and Methods describes
the quantification of CAM vasculature.
Mouse Xenografts. All animal procedures were approved by the ethical
commission of the University of Turin and the Italian Ministry of Health.
COLO205 (5 × 106 cells per mouse) or SK-MEL-28 (8 × 106 cells per mouse)
were injected s.c. into the right posterior flanks of 7-wk-old immunodefi-
cient NOD/SCID female mice (6 mice per group; Charles River). Tumor for-
mation was monitored twice per week, and tumor volume based on caliper
measurements was calculated by the modified ellipsoid formula (i.e., half
the product of length and the square of width). When tumors reached
a volume of approximately 150 to 200 mm3, mice were randomized and
treated by daily gavage for 2 wk with vehicle (1% methylcellulose, 5%
DMSO in sterile water) or PLX4720 60 mg/kg.
Fig. 6. PLX4720 treatment down-regulates the expression of proangiogenic factors. (A) Expression of proangiogenic factors was evaluated by real-time PCR.
Cells carrying BRAFV600E, COLO205, and SK-MEL-28, and BRAF WT DiFi cells were treated for 24 h with PLX4720. Data are expressed as relative quantity (RQ) of
PLX4720 compared with vehicle-treated samples. Bars show mean ± SD of triplicate measurements. (B) Quantification of secreted VEGF-A in cells supernatant
by ELISA after 24 h of the indicated treatments. Data are expressed in pg/mL and bars represent mean ± SEM of duplicate observations. The representative of
two experiments is shown. (C) Biochemical analysis of phospho-p90RSK1, -eIF4E, and -4EBP1 in COLO205, SK-MEL-28, and DiFi cells. Protein loading was
normalized by vinculin. Starved cells were stimulated for 30 min with 2.5% FBS plus 1 μM PLX4720 or vehicle.
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Hypoxia Assay. Tumor hypoxia was detected by the formation of pimoni-
dazole adducts with a Hypoxyprobe-1 Plus (FITC-mAb) kit (HP2-200; HPI)
following manufacturer instructions. Details about the procedure and
quantification are provided in SI Materials and Methods.
Tumor Vasculature Quantification. The following primary antibodies were used
for histological analysis: rabbit anti-von Willebrand Factor (vWF; A0082;
DakoCytomation), mouse anti–HLA-ABC antigen (M0736; DakoCytomation),
rabbit anti-Ki67 (RM-9106-F0; Thermo Scientific) rat anti-CD31 (Pecam-1;
550274BD; Pharmingen), anti-NG2 (chondroitin sulfate proteoglycan poly-
clonal; AB5320; Chemicon). Quantifications on tumor vasculature were per-
formed with Image-Pro Plus 6.2 software (Media Cybernetics). The surface
area occupied by vessels was quantified as surface area of anti-CD31 antibody
staining compared with total tissue area visualized by DAPI. For each animal,
the total vessel area of at least four field/images was quantified.
Quantification of blood vessel lumen diameter was performed on single
stack images with Image-Pro Plus 6.2 software (Media Cybernetics). This
analysis was performed with the same images used for determination of
surface area occupied by vessels.
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SI Materials and Methods
Cell Culture. hTERT-HME1 cells were purchased from American
Type Culture Collection and were cultured in growth medium
containing DMEM/F-12 (Invitrogen) supplemented with 20 ng/
mL EGF, 10 μg/mL insulin, and 100 μg/mL hydrocortisone.
COLO205 and SK-MEL-28 cell lines were purchased from
American Type Culture Collection and cultured in RPMI-1640
medium (Invitrogen). DiFi cells were supplied by José Baselga
(Vall d’Hebron University, Barcelona, Spain) and cultured in
Ham F-12 medium (Clonetics/Cambrex Bio Science). All cell
media were supplemented with 10% FBS (Gibco/Invitrogen),
penicillin (500 U/mL), and streptomycin (100 μg/mL). Human
endothelial cells (ECs) were isolated from umbilical cord vein,
characterized, and grown as previously described (1).
Quantification of Chicken Chorioallantoic Membrane Vasculature. For
each chicken chorioallantoic membrane (CAM) sample, an ar-
bitrary “angiogenic index” was scored on the basis of microvessel
density and/or hemorrhages. Three categories were defined:
“low” index when microvessels or hemorrhages were absent,
“medium” when present in 30% to 70% of the surface area, or
“high” when occupying almost the complete area of the plug.
For histological analysis, samples were fixed in Zin-fixative and
frozen in cryostat embedding medium (Killik; Bio-Optica) to
prepare sections. Chicken ECs were visualized by the endothelial
marker von-Willebrand Factor and human epithelial cells by
HLA antigen (as detailed later). Single stack images were ac-
quired by confocal laser-scanning microscope (TCS SP2 with DM
IRE2; Leica) equipped with 20×, 40×, and 63×/1.40 HCX plan-
apochromat oil-immersion objective.
Quantification of ECs recruitment by hTERT-HME1 cell was
performed by Leica Confocal Software Histogram Quantification
Tool. In each picture, we drew a region of interest following anti-
HLA staining that recognized hTERT-HME1, and we quantified
the mean fluorescence intensity of anti-von Willebrand Factor
staining in the same area. Three images for each sample were
analyzed and the results are expressed as mean ± SEM of in-
dividual CAM.
Real-Time PCR. The total RNA was extracted from cell cultures or
fresh chorioallantoic membrane tissues by using the phenol-
chloroform method (Trizma; Sigma-Aldrich), treated with DN-
ase-free kit (Ambion; Applied Biosystems), and quantified with
an RNA 6000 Nano Assay kit in an Agilent 2100 Bioanalyzer
(Agilent Technologies). Single-strand cDNA synthesis from total
RNA was prepared by TaqMan reverse transcription reagents
(Applied Biosystems), as recommended by the manufacturer. All
quantitative real-time PCR reactions were performed with ABI
PRISM 7900 HT Fast Real-Time PCR system (Applied Bio-
systems). The expression of the housekeeping gene, TATA
Binding Protein (TBP), was used to normalize for variances in
input cDNA. All measurements were performed in technical du-
plicates. Raw data were analyzed using SDS2.2 software (Applied
Biosystems) to define relative quantity (RQ) and the gene ex-
pression data analysis program GEDAS (http://sourceforge.net/
projects/gedas) for hierarchical clustering.
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EC Migration.Chemotaxis assays with human ECs were performed
with a Boyden chamber, which consists of a 48-well micro-
chemotaxis chamber (Neuroprobe) and polyvinylpyrrolidone-free
polycarbonate filters (Nucleopore; Corning Costar) with a pore
size of 8 μm coated with 1% gelatin. hTERT-HME1 WT or
BRAFV600E knock-in (KI; 1 × 106) were cultured for 36 h in
serum-free DMEM, and then supernatants were collected and
added in the lower compartment of the Boyden chamber. Rabbit
anti–hVEGF-A (500-P10; PeproTech) blocking antibody 10 μg/mL,
or unrelated immunoglobulins (X0903; DakoCytomation) were
added to cell supernatants. ECs cells were serum-starved over-
night, and 50 μL of 2.5 × 106 cells/mL suspension were added to
the upper compartment in serum-free medium. To test the effect
of PLX4720 on endothelium, ECs were treated for 24 h with 1
μM PLX4720 in starved condition and then stimulated with
complete medium or VEGF-A (R&D Systems) for migration.
After 5 h of incubation at 37 °C with 5% CO2, the upper surface
of the filters was scraped with a rubber policeman scraper, and
the filters were fixed and stained with Diff-Quick (Dade Behr-
ing). Four random fields of each sample in the lower surface of
the filters were counted at a magnification of 10× with a BX-60
microscope (Olympus) equipped with a color Qicam Fast 1394-
digital CCD camera (12 bit; QImaging). All samples were ana-
lyzed in triplicate and data are expressed as mean ± SD.
ELISA. Parental or BRAFV600E hTERT-HME1 (7 × 105) were
cultured for 24 h in serum-free DMEM. COLO205, SK-MEL-28,
and DiFi cells (5 × 105) were plated in six-well dishes and treated
for 24 h with 1 μM PLX4720, CoCl2 100 μM, the MEK inhibitor
AZD6244 100 nM, or vehicle in RPMI 1% serum. Supernatants
were collected and cells were counted to normalized VEGF-A
quantification on the total number of cells.
ELISA for VEGF-A was performed with a Quantikine im-
munoassay kit (DVE00; R&D Systems) following the manu-
facturer’s instructions.
PLX4720 Synthesis. PLX4720 was provided by Alberto Minassi and
Giovanni Appendino (Universitá del Piemonte Orientale, No-
vara, Italy) and synthesized as previously described (2).
Hypoxia Assay. Tumor hypoxia was detected by the formation of
pimonidazole adducts with Hypoxyprobe-1 Plus (FITC-mAb) kit
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(HP2-200; HPI) and following manufacturer instructions. Briefly,
mice were injected intraperitoneally with pimonidazole hydro-
chloride and euthanized after 90 min. Tumors were frozen in
cryostat embedding medium (Killik; Bio-Optica) for histological
analysis. The percentage hypoxic surface area was quantified
using Image-Pro Plus 6.2 software (Media Cybernetics) by
measuring pimonidazole-stained area compared with the total
tissues area. For each mouse, the hypoxic area was defined by the
sum of at least three fields at a magnification of 5× with an BX-60
microscope (Olympus) equipped with a color Qicam Fast 1394-
digital CCD camera (12 bit; QImaging). Individual animals were
used to calculate mean and SEM.
Tissue Perfusion. Blood vessel perfusion was detected by i.v. ad-
ministration of 200 μL of orange fluorescent microspheres
(FluoSpheres; Molecular Probes). After 2 min, the animals were
killed and tumor tissues were fixed by heart perfusion with ice-
cold PFA 2% (wt/vol). The distribution of the microspheres in
tumors was visualized by confocal microscopy by using 10-μm
sections. Tumor perfusion was quantified as colocalization signal
between microspheres and blood vessels on multiple stacks im-
ages with LAS AF software (Leica) maintaining the same area
(0.303 mm2) and fluorescent setting. At least 10 images at
a magnification of 40× were analyzed for each sample, with five
mice per treatment group.
Histological Analysis. Tumor tissues were fixed by heart perfusion
with ice-cold PFA 2% (wt/vol). Tissue slides (12 μm) were treated
following standard immunofluorescence or immunohistochem-
istry procedures. Briefly, slides were permeabilized in 0.2%
Triton X-100 (Sigma-Aldrich), treated for 5 to 20 min with 3%
hydrogen peroxide (Sigma-Aldrich) to quench endogenous per-
oxidases in immunohistochemistry experiments, and saturated in
3% BSA (wt/vol; Sigma-Aldrich).
For immunohistochemistry, secondary HRP-conjugate anti-
bodies (EnVision; DakoCytomation) were used, and the reaction
was visualized with the AEC kit (DakoCytomation). When
necessary, tissues were counterstained with Mayer hematoxylin
(Vector Laboratories), mounted on glass slides, and visualized
with a BX-60microscope (Olympus) equipped with a color Qicam
Fast 1394-digital CCD camera (12 bit; QImaging).
For immunofluorescence experiments, Alexa Fluor secondary
antibodies (Invitrogen) were used. Tissues were counterstained
with DAPI nucleic acid stain (Invitrogen), and analyses were
performed by using a Leica TCS SP2 AOBS confocal laser-
scanning microscope (Leica Microsystems).
Blood vessels coverage by pericytes was defined by the measure
of colocalization area between anti-CD31 and anti-NG2 staining
with Image-Pro Plus 6.2 software (Media Cybernetics). Final
results were normalized on total area occupied by vessels.
Proliferation Assay. COLO205, SK-MEL-28, and DiFi cells (2.5 ×
103) were seeded in quadruplicate in 96-well plates in complete
medium. After 24 h, cells were treated for 96 h with increasing
concentrations of PLX4720 in RPMI 5% serum. ECs (2 × 103)
were seeded in starved condition and stimulated with serum or
VEGF-A (R&D Systems) with 1 μM PLX4720 or vehicle for
96 h. Cell viability was evaluated by a luminescence ATP assay
(Cell-Titer Glo; Promega). All luminescence were recorded by
the DTX 880-Multimode plate reader (Beckman-Coulter).
Western Blotting. Total protein lysates from tumor cells or xen-
ografts were obtained by warm Laemmli buffer extraction (SDS
5%, Tris-HCl 0.15 M, pH 6.8, 4% glycerol). Cell lysates (30 μg)
were separated by SDS/PAGE electrophoresis and transferred
to nitrocellulose membrane (Hybond-C Extra; Amersham Bio-
sciences). After blocking with 10% BSA, membranes were in-
cubated with primary antibodies overnight at 4 °C. The following
antibodies were used: mouse anti–phospho-p44/42 MAPK
(Erk1/2; Thr202/Tyr204; 9106; Cell Signaling), rabbit anti-p44/42
MAPK (Erk1/2; 9102; Cell Signaling), rabbit anti–phospho-AKT
(Ser473; 9271; Cell Signaling), rabbit anti–phospho-AKT
(Thr308; 2965; Cell Signaling), rabbit anti-AKT (9272; Cell
Signaling), rabbit anti–phospho-eIF4E (Ser209; 9741; Cell Sig-
naling), rabbit anti-eIF4E (9742; Cell Signaling), rabbit anti–
phospho-4EBP1 (Ser65; 9451; Cell Signaling), rabbit anti-
4EBP1 (9452; Cell Signaling), rabbit anti–phospho-p90RSK
(Ser380; 9D9; 9335; Cell Signaling), rabbit anti-p90RSK (9333;
Cell Signaling), goat anti-vinculin (N-19; sc-7649; Santa Cruz
Biotechnology), and rabbit anti–cleaved caspase-3 (Asp175;
9664; Cell Signaling). After incubation with peroxidase-conju-
gated secondary antibodies (305-035-003, diluted 1:15,000;
Jackson ImmmunoResearch), proteins were detected by ECL
(Perkin-Elmer).
1. Bussolino F, et al. (1992) Hepatocyte growth factor is a potent angiogenic factor which
stimulates endothelial cell motility and growth. J Cell Biol 119:629e641.
2. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with
potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041e3046.
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Fig. S1. BRAFV600E up-regulates the expression of proangiogenic factors in hTERT-HME1 BRAFV600E KI cells. Gene expression analysis was performed by real-
time PCR comparing parental hTERT-HME1 with two different BRAFV600E clones (KI-A and KI-B). The transcription profile was analyzed in cells plated on culture
dish or on CAM. Differentially modulated genes were selected and analyzed by hierarchical clustering. Data are plotted as relative quantity mean on a scale
from −15 to +15 fold change.
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Fig. S2. PLX4720 treatment does not influence blood vessel coverage by pericytes. Histological analysis of COLO205 xenografts before and after PLX4720
treatment. (A) Immunofluorescence analysis upon staining with the CD31 endothelial marker (green) and NG-2 pericyte marker (magenta) with colocalization
of the two markers. (Scale bar: 100 μm.) (B) Percentage areas of colocalization between CD31 and NG-2 stainings. Data are normalized on CD31 surface area.
Bars show mean ± SEM. Start point, n = 4 mice; vehicle, n = 6 mice; PLX4720, n = 6 mice.
Fig. S3. PLX4720 does not affect ECs proliferation and migration. Human ECs were used to evaluate migration and proliferation. ECs were stimulated by
serum (i.e., FBS) or 50 ng/mL VEGF-A and were treated with 1 μM PLX4720 or vehicle. EC migration is represented as mean number of migrated cells ± SD in
triplicate. Cells proliferation is shown as mean percentage of cells viability compared with untreated samples (SF) ± SD in quadruplicate. In both cases, rep-
resentative results of two independent experiments are shown.
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